Advertisement

Advertisement
Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

Lisa A. Carey, MD, and Sherene Loi, MD, PhD, on TNBC: Combination Immune Checkpoint Inhibitor Therapy

2019 ASCO: Low-Fat Diet May Reduce the Risk of Death From Breast Cancer in Postmenopausal Women

Excluding skin cancer, breast cancer is the most common cancer diagnosed in women in the United States. In 2019, the American Cancer Society estimates that about 268,600 new cases of breast cancer will be diagnosed in women, and about 41,760...

ARRS 2019: Short-Interval Follow-up MRI in Identifying Early-Stage Breast Cancer

When appropriate, short-interval follow-up magnetic resonance imaging (MRI) can be used to identify early-stage breast cancer and avoid unnecessary biopsies, according to a study presented by Lamb et al at the American Roentgen Ray Society (ARRS) 2019...

Addition of Tucidinostat to Exemestane in Advanced Hormone Receptor–Positive Breast Cancer

In the Chinese phase III ACE trial reported in The Lancet Oncology, Jiang et al found that the addition of the oral histone deacetylase inhibitor tucidinostat to exemestane improved progression-free survival in postmenopausal women with advanced hormone...

Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches

Postprogression Treatment of Estrogen Receptor–Positive Breast Cancer: Future Approaches

At the 2019 Miami Breast Cancer Conference, William J. Gradishar, MD, FASCO, presented a vision of the future in the treatment of advanced hormone receptor–positive breast cancer...

Final Analysis of the HannaH Trial: Perioperative Subcutaneous vs Intravenous Trastuzumab in HER2-Positive Early Breast Cancer

As reported in JAMA Oncology by Jackisch et al, the final analysis of the phase III HannaH trial indicated comparable efficacy and safety of perioperative subcutaneous (SC) vs intravenous (IV) trastuzumab in ERBB2 (HER2)-positive early breast cancer....

Advertisement


Advertisement